Table 4. Gastric cancer-related treatment and supportive care costs^* (USD).

USD = United States dollar; SD = standard deviation; PET = positron emission tomography; CT = computed tomography; MRI = magnetic resonance imaging. ^*Gastric cancer-related treatment costs included radiation, chemotherapy and biologic therapy costs; gastric cancer-related supportive care costs included palliative surgery, growth factors, iron supplements, antibiotics, antivirals, antiemetics, antifungals, pain medications, bisphosphonates, nutritional support, PET, endoscopy, CT, MRI, radiography, and blood tests. ^†Patients receiving cancer-related treatments after the first-line chemotherapy completion date categorized as 'additionally treated,' otherwise considered as 'supportive care only.' ^‡Gastric cancer-related treatment and supportive care costs were assessed during the following pre-defined periods of assessment: (1) Overall follow-up period: the period between the index gastric cancer diagnosis date and death or the end of the database (December 31, 2009), whichever occurred first; (2) Post-first-line chemotherapy period: the period between the day immediately following the first-line chemotherapy administration end date and death or the end of the database, whichever occurred first; (3) First-line chemotherapy period: the period between the gastric cancer index date and the first-line chemotherapy regimen end date; and (4) Second-line chemotherapy period: the period between the day immediately following the first-line chemotherapy regimen end date and the last date of the second-line chemotherapy regimen among patients who initiated second-line chemotherapy. ^§Patients with chemotherapy administration claims without a corresponding chemotherapy drug claim after the completion of first-line chemotherapy were included in the supportive care only group. However, the chemotherapy administration costs have been reported for these patients.